Collaboration between Pfizer and Evotec
Licence and collaboration agreement in tissue fibrosis
Evotec AG announced that it has signed an agreement on a four-year research collaboration with Pfizer Inc. in the field of tissue fibrosis.
Under the terms of this licence and collaboration agreement, scientists at Evotec and Pfizer will explore potential novel mechanisms as targeted anti-fibrotics in multi-organ fibrosis. Evotec will contribute its drug discovery platform whereas Pfizer will provide key technologies and industrial scope as well as pharmaceutical development and marketing expertise.
Financial terms of the collaboration include an upfront payment and potential milestone payments from Pfizer based on the achievement of specific development and sales milestones.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.